{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:20:36Z","timestamp":1792815636647,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009777","name":"Region Halland","doi-asserted-by":"publisher","award":["HALLAND-859 921"],"award-info":[{"award-number":["HALLAND-859 921"]}],"id":[{"id":"10.13039\/501100009777","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The incidence of cirrhosis for individuals in Sweden has previously been reported as stable\/low among European countries. However, Swedish population-based studies are scarce and none of them included data from the most recent decade (2010\u20132019). We aimed to describe the incidence and aetiology of cirrhosis in the Halland region from 2011 to 2018, and to describe the severity and prevalence of liver-related complications and other primary comorbidities at the time of cirrhosis diagnosis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a retrospective cohort study of all patients with cirrhosis in Halland, which has a population of 310,000 inhabitants. Medical records and histopathology registries were reviewed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 598 patients with cirrhosis were identified. The age-standardised incidence was estimated at 23.2 per 100,000 person-years (95% CI 21.3\u201325.1), 30.5 (95% CI 27.5\u201333.8) for men and 16.4 (95% CI 14.3\u201318.7) for women. When stratified by age, the highest incidence rates were registered at age 60\u201369\u2009years. Men had a higher incidence rate for most age groups when compared to women. The most common aetiology was alcohol (50.5%), followed by cryptogenic cirrhosis (14.5%), hepatitis C (13.4%), and non-alcoholic fatty liver disease (5.7%). Most patients had at least one liver-related complication at diagnosis (68%). The most common comorbidities at diagnosis were arterial hypertension (33%), type 2 diabetes (29%) and obesity (24%).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Based on previous Swedish studies, our results indicate that the incidence of cirrhosis in Sweden might be considerably higher than previously reported. It is uncertain if the incidence of cirrhosis has previously been underestimated or if an actual increment has occurred during the course of the most recent decade. The increased incidence rates of cirrhosis reported in Halland are multifactorial and most likely related to higher incidence rates among the elderly. Pre-obesity and obesity are common in cirrhosis and non-alcoholic fatty liver disease has become an important cause of cirrhosis in Halland.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12876-020-01239-6","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T10:07:53Z","timestamp":1585908473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"Juan","family":"Vaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berne","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Buchebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Midl\u00f6v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,3]]},"reference":[{"issue":"1","key":"1239_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151\u201371.","journal-title":"J Hepatol"},{"issue":"5 Suppl 1","key":"1239_CR2","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","volume":"127","author":"G Fattovich","year":"2004","unstructured":"Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35\u201350.","journal-title":"Gastroenterology"},{"issue":"3","key":"1239_CR3","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jhep.2018.05.011","volume":"69","author":"L Pimpin","year":"2018","unstructured":"Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L, Sheron N, Committee EHS. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69(3):718\u201335.","journal-title":"J Hepatol"},{"issue":"8","key":"1239_CR4","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1080\/00365520902912571","volume":"44","author":"SA Gunnarsdottir","year":"2009","unstructured":"Gunnarsdottir SA, Olsson R, Olafsson S, Cariglia N, Westin J, Thjodleifsson B, Bjornsson E. Liver cirrhosis in Iceland and Sweden: incidence, aetiology and outcomes. Scand J Gastroenterol. 2009;44(8):984\u201393.","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"1239_CR5","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1111\/apt.13635","volume":"43","author":"E Nilsson","year":"2016","unstructured":"Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Incidence, clinical presentation and mortality of liver cirrhosis in southern Sweden: a 10-year population-based study. Aliment Pharmacol Ther. 2016;43(12):1330\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"1239_CR6","volume-title":"Annual Epidemiological Reports","author":"Public Health Agency of Sweden","year":"2018","unstructured":"Public Health Agency of Sweden. Annual Epidemiological Reports. 2018. www.folkhalsomyndigheten.se."},{"issue":"11","key":"1239_CR7","doi-asserted-by":"publisher","first-page":"e0143084","DOI":"10.1371\/journal.pone.0143084","volume":"10","author":"T Andersson","year":"2015","unstructured":"Andersson T, Ahlbom A, Carlsson S. Diabetes prevalence in Sweden at present and projections for year 2050. PLoS One. 2015;10(11):e0143084.","journal-title":"PLoS One"},{"issue":"6","key":"1239_CR8","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3109\/00365521.2012.661759","volume":"47","author":"A Dam Fialla","year":"2012","unstructured":"Dam Fialla A, Schaffalitzky de Muckadell OB, Lassen T. A: incidence, etiology and mortality of cirrhosis: a population-based cohort study. Scand J Gastroenterol. 2012;47(6):702\u20139.","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"1239_CR9","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1080\/00365520701478014","volume":"42","author":"JW Haukeland","year":"2007","unstructured":"Haukeland JW, Lorgen I, Schreiner LT, Frigstad SO, Brandsaeter B, Bjoro K, Bang C, Raknerud N, Konopski Z. Incidence rates and causes of cirrhosis in a Norwegian population. Scand J Gastroenterol. 2007;42(12):1501\u20138.","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"1239_CR10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/ajg.2013.405","volume":"109","author":"S Ratib","year":"2014","unstructured":"Ratib S, West J, Crooks CJ, Fleming KM. Diagnosis of liver cirrhosis in England, a cohort study, 1998-2009: a comparison with cancer. Am J Gastroenterol. 2014;109(2):190\u20138.","journal-title":"Am J Gastroenterol"},{"key":"1239_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejro.2015.05.002","volume":"2","author":"A Huber","year":"2015","unstructured":"Huber A, Ebner L, Heverhagen JT, Christe A. State-of-the-art imaging of liver fibrosis and cirrhosis: a comprehensive review of current applications and future perspectives. Eur J Radiol Open. 2015;2:90\u2013100.","journal-title":"Eur J Radiol Open"},{"issue":"i-xii","key":"1239_CR12","first-page":"1","volume":"894","author":"Obesity: preventing and managing the global epidemic","year":"2000","unstructured":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894(i-xii):1\u2013253.","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"1","key":"1239_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2005.05.009","volume":"43","author":"R de Franchis","year":"2005","unstructured":"de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43(1):167\u201376.","journal-title":"J Hepatol"},{"issue":"4","key":"1239_CR14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846\u201354.","journal-title":"Hepatology"},{"issue":"5","key":"1239_CR15","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","volume":"62","author":"S McPherson","year":"2015","unstructured":"McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148\u201355.","journal-title":"J Hepatol"},{"issue":"6","key":"1239_CR16","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski MS, Torriani FJ, Dieterich DT, Thomas DL, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325.","journal-title":"Hepatology"},{"issue":"8","key":"1239_CR17","doi-asserted-by":"publisher","first-page":"e2877","DOI":"10.1097\/MD.0000000000002877","volume":"95","author":"Y Peng","year":"2016","unstructured":"Peng Y, Qi X, Guo X. Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Medicine (Baltimore). 2016;95(8):e2877.","journal-title":"Medicine (Baltimore)"},{"key":"1239_CR18","volume-title":"Revision of the European Standard Population \u2014 Report of Eurostat's task force. ISBN 978\u201392\u201379-31094-2","author":"European Commission","year":"2013","unstructured":"European Commission. Revision of the European Standard Population \u2014 Report of Eurostat's task force. ISBN 978\u201392\u201379-31094-2; 2013."},{"issue":"5","key":"1239_CR19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/CEJ.0000000000000250","volume":"26","author":"E Crocetti","year":"2017","unstructured":"Crocetti E, Dyba T, Martos C, Randi G, Rooney R, Bettio M. The need for a rapid and comprehensive adoption of the revised European standard population in cancer incidence comparisons. Eur J Cancer Prev. 2017;26(5):447\u201352.","journal-title":"Eur J Cancer Prev"},{"key":"1239_CR20","volume-title":"Registered and unregistered alcohol in the counties of Sweden 2001-2016. Report 165. Centralf\u00f6rbundet f\u00f6r alkohol- och narkotikaupplysning","author":"B Trolldal","year":"2017","unstructured":"Trolldal B, Guttormsson U, Leifman H. Registered and unregistered alcohol in the counties of Sweden 2001-2016. Report 165. Centralf\u00f6rbundet f\u00f6r alkohol- och narkotikaupplysning; 2017."},{"key":"1239_CR21","doi-asserted-by":"publisher","first-page":"1942648","DOI":"10.1155\/2018\/1942648","volume":"2018","author":"H Hagstrom","year":"2018","unstructured":"Hagstrom H, Elfwen O, Hultcrantz R, Stal P. Steatohepatitis is not associated with an increased risk for fibrosis progression in nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2018;2018:1942648.","journal-title":"Gastroenterol Res Pract"},{"issue":"6","key":"1239_CR22","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstrom","year":"2017","unstructured":"Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R, Kechagias S. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265\u201373.","journal-title":"J Hepatol"},{"issue":"4","key":"1239_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1665-2681(19)31748-X","volume":"8","author":"SH Caldwell","year":"2009","unstructured":"Caldwell SH, Lee VD, Kleiner DE, Al-Osaimi AM, Argo CK, Northup PG, Berg CL. NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol. 2009;8(4):346\u201352.","journal-title":"Ann Hepatol"},{"issue":"3","key":"1239_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jhep.2017.11.018","volume":"68","author":"PJ Thuluvath","year":"2018","unstructured":"Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y. Is cryptogenic cirrhosis different from NASH cirrhosis? J Hepatol. 2018;68(3):519\u201325.","journal-title":"J Hepatol"},{"issue":"3","key":"1239_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jhep.2017.12.006","volume":"68","author":"S Caldwell","year":"2018","unstructured":"Caldwell S, Marchesini G. Cryptogenic vs. NASH-cirrhosis: the rose exists well before its name. J Hepatol. 2018;68(3):391\u20132.","journal-title":"J Hepatol"},{"issue":"8","key":"1239_CR26","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/00365521.2019.1649454","volume":"54","author":"E Nilsson","year":"2019","unstructured":"Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Risk and outcome of hepatocellular carcinoma in liver cirrhosis in southern Sweden: a population-based study. Scand J Gastroenterol. 2019;54(8):1027\u201332.","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"1239_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/apt.13505","volume":"43","author":"M Walker","year":"2016","unstructured":"Walker M, El-Serag HB, Sada Y, Mittal S, Ying J, Duan Z, Richardson P, Davila JA, Kanwal F. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther. 2016;43(5):621\u201330.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"1239_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.14740\/gr1074w","volume":"11","author":"D Guss","year":"2018","unstructured":"Guss D, Sherigar J, Mohanty SR. Missed diagnosis of liver cirrhosis leads to disparities in Care for Older Patients. Gastroenterology Res. 2018;11(5):333\u20139.","journal-title":"Gastroenterology Res"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01239-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-020-01239-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01239-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T23:19:04Z","timestamp":1617405544000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-020-01239-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1239"],"URL":"https:\/\/doi.org\/10.1186\/s12876-020-01239-6","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]},"assertion":[{"value":"20 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Central Ethical Review in Sweden (Decision Number 2018\/1117). For this type of study formal consent is not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}